欢迎访问行业研究报告数据库

行业分类

当前位置:首页 > 报告详细信息

找到报告 1 篇 当前为第 1 页 共 1

全球肝炎药物市场报告(2015-2019年)

Global Hepatitis Drugs Market 2015-2019

加工时间:2015-12-17 信息来源:EMIS 索取原文[118 页]
关键词:肝炎;医学病症;病毒性肝炎;自体免疫疾病;酒精;处方药;有毒物质
摘 要:Hepatitis is a medical condition where the liver is predominantly affected. It can also affect the digestive system and brain. The most common hepatitis is viral hepatitis, which can be caused by one of five hepatotropic viruses: hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. Non-viral hepatitis can be caused by autoimmune diseases, alcohol, prescription medications, and toxic substances.
目 录:

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Product offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Disease overview

Understanding the disease

Classification

Mode of transmission

Epidemiology

Diagnosis

Symptoms

Treatment

PART 06: Key marketed drugs

Hepatitis A

Hepatitis B

Hepatitis C

PART 07: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 08: Market segmentation by type

Hepatitis A

Hepatitis B

Hepatitis C

PART 09: Market segmentation by MOA

Virus-specific agents

Non-specific agents

PART 10: Geographical segmentation

PART 11: Market drivers

PART 12: Impact of drivers

PART 13: Market challenges

PART 14: Impact of drivers and challenges

PART 15: Market trends

PART 16: Vendor landscape

Competitive scenario

Gilead Sciences

Johnson & Johnson

F. Hoffman-La Roche

Merck

GlaxoSmithKline

Vertex Pharmaceuticals

Novartis

Other prominent vendors

PART 17: Key vendor analysis

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

Novartis

Roche

Vertex Pharmaceuticals

PART 18: Appendix

List of abbreviations

PART 19: Explore Technavio

© 2016 武汉世讯达文化传播有限责任公司 版权所有
客服中心

QQ咨询


点击这里给我发消息 客服员


电话咨询


027-87841330


微信公众号




展开客服